Comparing two aspirin doses in older heart disease patients
Part of Heart & circulation clinical trials.
This study compares whether a lower dose of aspirin (50 mg) works as well as a standard dose (100 mg) for older adults who have had heart attacks, strokes, or other heart and blood vessel problems. The goal is to find the safest effective dose to prevent future events.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years old or older
- You have a diagnosis of heart disease, stroke, or blood vessel disease (such as a previous heart attack, stent placement, bypass surgery, or stroke)
- You have been taking aspirin regularly for at least 1 year to prevent future heart or stroke events
- You have had recent blood tests and urine tests (within 3 months) checking your blood count, liver, kidney, and heart function
- You are willing and able to take study medication as prescribed and attend follow-up visits
- You do not have a severe allergy to aspirin or bleeding disorders that would make participation unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether taking your daily aspirin in the morning or at bedtime changes heart and circulation outcomes. It is meant to see if timing matters for people who already take aspirin every day.
This trial tests whether taking just one blood thinner (clopidogrel) is as safe and effective as taking two (clopidogrel plus aspirin) for older adults or people at high bleeding risk who have had a drug-coated balloon procedure to open blocked heart arteries.
This trial tests whether a daily aspirin and a statin medicine can help prevent heart problems in people with high calcium buildup in their heart arteries. It is for people aged 40 to 75 who have a high coronary calcium score (300 or more) and at least one additional risk factor like diabetes or high blood pressure.
This Phase 3 study tests whether colchicine and a special type of aspirin can lower the risk of future heart attacks, strokes, or other major heart problems in people with type 2 diabetes who have not had a prior heart event. It aims to reduce cardiovascular risk using medicines that may calm inflammation and protect blood vessels.
This trial tests whether a lower dose of the blood thinner rivaroxaban works as well as the standard dose for people 70 and older with atrial fibrillation (an irregular heartbeat). The goal is to find the safest dose to prevent strokes while reducing bleeding risks.
This trial tests whether daily aspirin is safe and effective for people who have stable (chronic) coronary artery disease but cannot have procedures to open blocked arteries. It may help reduce future heart problems, while also checking for side effects and risks from aspirin.
Hear when a new Atherosclerotic Cardiovascular Disease (ASCVD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.